VC
ACTU

Voss Capital’s Actuate Therapeutics ACTU Stock Holding History

Voss Capital’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Hold
1,725,000
– – 0.12% 45
2026
Q1 		$4.73M Buy
1,725,000
+425,000
+33% +$1.76M 0.25% 37
2025
Q4 		$7.96M Buy
1,300,000
+403,722
+45% +$2.77M 0.38% 33
2025
Q3 		$6M Buy
896,278
+610,138
+213% +$4.42M 0.3% 36
2025
Q2 		$1.75M Buy
286,140
+143,759
+101% +$1.26M 0.12% 44
2025
Q1 		$964K Buy
142,381
+87,135
+158% +$700K 0.07% 51
2024
Q4 		$440K Buy
+55,246
New +$451K 0.03% 42

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

Voss Capital's ACTU Position: Q2 2026 in Review

Voss Capital held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 1,725,000 shares worth $2.64M. The position accounts for 0.12% of the portfolio, ranked #45.

Voss Capital first reported a position in ACTU in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.96M in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Voss Capital held 1,725,000 shares of Actuate Therapeutics worth $2.64M as of Q2 2026.
  • Voss Capital left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up 0.12% of Voss Capital's portfolio in Q2 2026, its #45 holding.
  • Voss Capital first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Voss Capital's Actuate Therapeutics position peaked at $7.96M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.